Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus

다국어 초록 (Multilingual Abstract)

Background We performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes mellitus (T2DM).
Methods We cross-sectionally analyzed 336 patients with T2DM. Intact glucagon-like peptide 1 (iGLP-1) and intact glucose-dependent insulinotropic polypeptide (iGIP) levels were measured in a fasted state and 30 minutes after ingestion of a standard mixed meal. The differences between 30 and 0 minute iGLP-1 and iGIP levels were indicated as ΔiGLP-1 and ΔiGIP.
Results In simple correlation analyses, fasting iGLP-1 was positively correlated with glucose, C-peptide, creatinine, and triglyceride levels, and negatively correlated with estimated glomerular filtration rate. ΔiGLP-1 was positively correlated only with ΔC-peptide levels. Fasting iGIP showed positive correlations with glycosylated hemoglobin (HbA1c) and fasting glucose levels, and negative correlations with ΔC-peptide levels. ΔiGIP was negatively correlated with diabetes duration and HbA1c levels, and positively correlated with Δglucose and ΔC-peptide levels. In multivariate analyses adjusting for age, sex, and covariates, fasting iGLP-1 levels were significantly related to fasting glucose levels, ΔiGLP-1 levels were positively related to ΔC-peptide levels, fasting iGIP levels were related to fasting C-peptide levels, and ΔiGIP levels were positively related to ΔC-peptide and Δglucose levels.
Conclusion Taken together, intact incretin levels are primarily related to C-peptide and glucose levels. This result suggests that glycemia and insulin secretion are the main factors associated with intact incretin levels in T2DM patients.

참고문헌 (Reference)

1 Levey AS, "Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate" 145 : 247-254, 2006

2 Nauck MA, "The incretin effect in healthy individuals and those with type 2 diabetes : physiology, pathophysiology, and response to therapeutic interventions" 4 : 525-536, 2016

3 Creutzfeldt W, "The incretin concept today" 16 : 75-85, 1979

4 Calanna S, "Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes : systematic review and meta-analysis of clinical studies" 36 : 3346-3352, 2013

5 Calanna S, "Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus : systematic review and meta-analyses of clinical studies" 56 : 965-972, 2013

6 Vilsboll T, "Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients" 50 : 609-613, 2001

7 Nauck MA, "Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus" 91 : 301-307, 1993

8 Alssema M, "Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT" 169 : 421-430, 2013

9 Vollmer K, "Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance" 57 : 678-687, 2008

10 Wu T, "Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes : stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity" 106 : e3-e6, 2014

11 Meier JJ, "Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function" 59 : 1117-1125, 2010

12 Vardarli I, "Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as"isoglycemic"intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes" 96 : 945-954, 2011

13 Hutson WR, "Influence of gender and menopause on gastric emptying and motility" 96 : 11-17, 1989

14 Nagai E, "Incretin responses to oral glucose load in Japanese non-obese healthy subjects" 2 : 20-28, 2011

15 Nauck MA, "Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses" 63 : 492-498, 1986

16 Creutzfeldt W, "Gut hormones and diabetes mellitus" 8 : 149-177, 1992

17 Qualmann C, "Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose)" 30 : 892-896, 1995

18 Seino Y, "GIP and GLP-1, the two incretin hormones : similarities and differences" 1 : 8-23, 2010

19 Shimodaira M, "Effects of short-term intensive glycemic control on insulin, glucagon, and glucagon-like peptide-1 secretion in patients with type 2 diabetes" 36 : 734-738, 2013

20 Toft-Nielsen MB, "Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients" 86 : 3717-3723, 2001

21 Deacon CF, "Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide" 85 : 3575-3581, 2000

22 Lynn FC, "Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats" 50 : 1004-1011, 2001

23 Vilsbøll T, "Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients" 45 : 1111-1119, 2002

24 Legakis IN, "Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes" 26 : 252-, 2003

25 Deacon CF, "Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects" 44 : 1126-1131, 1995

26 Baggio LL, "Biology of incretins : GLP-1 and GIP" 132 : 2131-2157, 2007

27 Lynn FC, "A novel pathway for regulation of glucose-dependent insulinotropic polypeptide(GIP)receptor expression in beta cells" 17 : 91-93, 2003